Roth MKM resumed coverage of Journey Medical with a Buy rating and $11 price target. The company is positioned to be a “best-in-class” oral treatment for rosacea, with clinical superiority and an expected expanded label over current market leader Oracea, the analyst tells investors in a research note. The firm estimates DFD-29 will generate at least $200M annually in sales by 2028. DFD-29 has a November 4 FDA action date and should push the company to profitability in 2025, contends Roth.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DERM:
- Journey Medical Corp Shareholders Back Key Proposals
- Biotech Alert: Searches spiking for these stocks today
- Journey Medical Corporation to Participate in the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company Showcase
- Journey Medical reports Q1 EPS (53c), consensus (23c)
- DERM Upcoming Earnings Report: What to Expect?